We compared the anti-tumor response of NKG2A+ vs. NKG2A− NK cell subsets in the CD107a assays to test whether licensing by NKG2A can have a positive effect on NK cell degranulation against HLA-E negative breast cancer targets. Here, HLA-E is linked to breast carcinoma.